Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

5.330 -0.950 (-15.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 Next >
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes
INmune Bio stock rose sharply on high volume ahead of topline Phase 2 trial data for XPro in early Alzheimer's, expected on June 30. 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Earnings Scheduled For May 8, 2025
Via Benzinga
What to Expect from INmune Bio's Earnings
Via Benzinga
INmune Bio: Q4 Earnings Insights
Via Benzinga
A Preview Of INmune Bio's Earnings
Via Benzinga
Earnings Outlook For INmune Bio
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week
INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
INmune Bio's Earnings Outlook
Via Benzinga
INmune Bio Earnings Perspective: Return On Capital Employed
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Earnings Scheduled For March 27, 2025
Via Benzinga
C-Suite Buy of the Week: Executive Moves from Biotech to Banking
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Why Is Elevai Labs (ELAB) Stock Up Today?
Elevai Labs is soaring on an intriguing licensing agreement with INmune Bio, but the narrative presents a mixed bag for ELAB stock. 
Via InvestorPlace
Why Elevai Labs Stock Is Trading Higher
Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! 
Via InvestorPlace
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease
David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
The 7 Best Biotech Stocks for Personalized Medicine Investors
Personalized Medicine Stocks Promise to Make Healthcare More Individualized with therapeutics based on individual genetics. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.